

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)



(10) International Publication Number
WO 2020/157652 A2

(51) International Patent Classification:

C07D 231/40 (2006.01) C07D 413/14 (2006.01)
C07D 401/12 (2006.01) C07D 417/12 (2006.01)
C07D 401/14 (2006.01) C07D 417/14 (2006.01)
C07D 403/12 (2006.01) C07D 471/04 (2006.01)
C07D 403/14 (2006.01) C07D 487/04 (2006.01)
C07D 405/12 (2006.01) C07D 513/04 (2006.01)
C07D 405/14 (2006.01) A61K 31/415 (2006.01)
C07D 413/12 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2020/050653

(22) International Filing Date:

28 January 2020 (28.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/799,455 31 January 2019 (31.01.2019) US
62/959,042 09 January 2020 (09.01.2020) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, NY 10017 (US).

(72) Inventors: **BEHENNA, Douglas Carl**; c/o Pfizer Inc.,
10777 Science Center Drive, San Diego, CA 92121 (US).
FREEMAN-COOK, Kevin Daniel; c/o Pfizer Inc., 10777
Science Center Drive, San Diego, CA 92121 (US). **HOFF-**
MAN, Robert Louis; c/o Pfizer Inc., 10777 Science Center
Drive, San Diego, CA 92121 (US). **NAGATA, Asako**; c/
o Pfizer Inc., 10777 Science Center Drive, San Diego, CA
92121 (US). **NINKOVIC, Sacha**; c/o Pfizer Inc., 10777
Science Center, San Diego, CA 92121 (US). **SUTTON,**
Scott Channing; c/o Pfizer Inc., 10777 Science Center Drive,
San Diego, CA 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.** et al.; PFIZER INC., 235
East 42nd Street, MS 235/9/S20, New York, NY 10017
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: CDK2 INHIBITORS



(57) Abstract: This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R¹, R² and R³ are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.



WO 2020/157652 A2